Mode
Text Size
Log in / Sign up

Sarcopenia is associated with 2.30 higher odds of cognitive impairment in Latin American adultsSarcopenia Linked to Higher Risk of Cognitive Impairment

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that sarcopenia is associated with significantly higher odds of cognitive impairment in Latin American adults.

This systematic review and meta-analysis evaluated the association between sarcopenia and cognitive impairment among 13,395 community-dwelling adults in Latin American populations across 8 studies. The analysis focused on identifying the strength of the link between muscle mass loss and cognitive decline.

The meta-analysis reported a pooled odds ratio of 2.30 (95% CI: 1.68-3.15) for cognitive impairment associated with sarcopenia. Specifically, those with sarcopenia by EWGSOP2 criteria showed even higher odds of cognitive impairment (OR = 2.96; 95% CI: 2.15-4.08, P < 0.001). Additionally, the odds for probable cognitive impairment were found to be 2.56 (95% CI: 1.85-3.53, P < 0.001) in individuals with sarcopenia.

A primary limitation noted by the authors was the scarcity of evidence specifically regarding Latin American populations prior to this study. While the association is statistically significant, it does not establish a direct causal relationship between sarcopenia and cognitive impairment. These findings suggest that screening for sarcopenia may be clinically relevant for identifying at-risk individuals in Latin American regions.

How this fits prior evidence

This meta-analysis addresses a gap by providing specific data on Latin American populations, where evidence was previously scarce. It complements prior coverage regarding the risks of sarcopenia, such as the finding that sarcopenia doubles mortality risk in patients with diabetes. While previous reports highlighted interventions like whey protein and vitamin D to improve sarcopenia outcomes, this study reinforces the clinical importance of identifying sarcopenia as a significant indicator for cognitive impairment.

Researchers looked at the link between sarcopenia, which is the loss of muscle mass and strength, and cognitive health. They analyzed data from over 13,000 middle-aged and older adults living in Latin American communities. This large review combined results from several different studies to get a clearer picture of how these two conditions relate.

The findings show that people with sarcopenia have significantly higher odds of experiencing cognitive impairment. Specifically, the data showed that those with muscle loss were more than twice as likely to have cognitive issues compared to those without it. These results remained consistent across different ways of measuring both muscle health and mental clarity.

It is important to remember that this study shows a link between these two conditions rather than proving that one causes the other. Because this was a large review of existing data, it provides a broad look at the situation for many people. You should talk with a healthcare provider to understand how muscle health might affect your own long-term wellness.

What this means for you:
Sarcopenia is linked to significantly higher odds of cognitive impairment in middle-aged and older adults.

Common questions

What is the link between muscle loss and brain health?

The study found a strong association between sarcopenia and cognitive impairment. Specifically, people with sarcopenia had over twice the odds of experiencing cognitive issues. This suggests that maintaining muscle mass may be important for overall health as people age.

Who was included in this study?

The research included 13,395 community-dwelling adults who were middle-aged or older. The participants were specifically from Latin American populations, providing a large amount of data to help identify the link between muscle loss and cognitive health.

Does having sarcopenia cause cognitive impairment?

The study shows an association between these two conditions, but it does not prove that one causes the other. While the link is clear in the data, you should speak with a doctor to understand how these factors specifically affect your health.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
OBJECTIVES: Reduction in skeletal muscle mass, strength, and function, such as sarcopenia, have been associated with cognitive impairment. In Latin America (LATAM), evidence remains scarce, a critical gap given the region's rapid demographic aging. Therefore, the present study aims to evaluate the association between sarcopenia and cognitive impairment among middle-aged and older adults in LATAM countries. DESIGN: A systematic review and meta-analysis. SETTING: A systematic literature search was conducted using PubMed, Web of Science, EMBASE, LILACS, SciELO and sources of grey literature. The association between sarcopenia and cognitive impairment (odds ratio) was pooled in a meta-analysis using a random-effects model. The quality of the methodology used in each study was evaluated using the JBI Critical Appraisal Tools. PARTICIPANTS: Middle-aged and older adults from cross-sectional and longitudinal studies conducted in Latin American populations. MEASURES: The primary outcome was the pooled association between sarcopenia and cognitive impairment. RESULTS: A total of 8 studies and 13,395 community-dwelling adults were included. The meta-analysis showed that sarcopenia was associated with higher odds of cognitive impairment (OR = 2.30; 95% CI: 1.68-3.15). However, the magnitude of this association varied according to definition as probable cognitive impairment (OR = 2.56, 95% CI: 1.85-3.53, P < 0.001) and diagnosis criteria of sarcopenia by EWGSOP2 (OR = 2.96; 95% CI: 2.15-4.08, P < 0.001). CONCLUSION: In LATAM, sarcopenia doubles the odds of cognitive impairment in adults. Future research must elucidate the inflammatory, oxidative, and mitochondrial pathways linking muscle and brain health.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.